Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 209

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 209
---
 of 84,059 shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq on December 20, 2024, to certain institutional investors as a condition to the exercise of Preferred Warrants held thereby. On January 6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares of Common Stock, with an exercise price of $5.82 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025, to an institutional investor as a condition to the exercise of Preferred Warrants held thereby. Such number of shares gives effect to the Reverse Stock Split. Reverse Stock Split At 12:01 a.m. Eastern time on January 8, 2025, we effected the Reverse Stock Split pursuant to which each 100 shares of our Common Stock outstanding immediately prior thereto was converted into 1 share of our Common Stock outstanding immediately thereafter. Factors Affecting Our Performance The Company believes that its performance and future success depend on several factors that present significant opportunities for the Company but also pose risks and challenges. These include, among others:

| ● | the extent to which the Company develops, in-licenses or acquires other product candidates and technologies in its product candidate pipeline; |

| ● | the costs and timing of process development and manufacturing scale-up activities associated with the Company’s product candidates and other programs as the Company advances them through preclinical and clinical development; |

| ● | the number and development requirements of product candidates that the Company may pursue; |

| ● | the costs, timing and outcome of regulatory review of the Company’s product candidates; |

| ● | the Company’s potential headcount growth and associated costs as it expands its R&D capabilities,  maintains the administrative functions required for a publicly traded company, and establishes and expands its commercial infrastructure and operations; |

| ● | the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of the Company’s product candidates for which the Company receives market approval; |

| ● | the revenue, if any, received from commercial sales of the Company’s product candidates for which it receives marketing approval; |

| ● | competition from other similar product candidates; and, |

| ● | ability to raise sufficient capital to maintain operations. |

131 Components of Results of Operations Revenue Predecessor and the Company have not recognized any revenue from any sources, including